*GZQJ

• Research type

  Research Study

• Full title

  A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-8)

• IRAS ID

  1012856

• Contact name

  Maryna Kvochka

• Contact email

  EU_lilly_clinical_trials@lilly.com

• Sponsor organisation

  Eli Lilly & Company

• Research summary

  GZQJ is a Phase 3b study with a 56-week treatment duration, which is designed to investigate the efficacy and safety of retatrutide, compared with placebo in participants with obesity, or overweight and at least 1 weight-related condition, for example, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
  The participants will be randomly assigned 2:2:1 to one of 2 doses of retatrutide or placebo and will administer their dose once weekly by subcutaneous injection for up to 56 weeks.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  25/LO/0703

• Date of REC Opinion

  3 Oct 2025

• REC opinion

  Further Information Favourable Opinion